Bleselumab

Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd:  0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection.

Bleselumab (0-1 μg/mL, 48 h) dose-depently inhibits PBMCs proliferation induced by soluble CD154^[2].

Bleselumab (0.1-10 mg/kg, i.v.) inhibits Delayed-type hypersensitivity (DTH) reaction in cynomolgus monkeys^[2].
Bleselumab (2 mg/kg, i.v.) prolongs renal allograft survival in Cynomolgus monkeys^[3].
Bleselumab (2 or 5 mg/kg, i.v.) together with Tacrolimus shows a longer median survival time (MST) than monotherapy^[3].

References:
[1]. Harland RC, et al. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 Jan;20(1):159-171.
[2]. Okimura K, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014 Jun;14(6):1290-9.
[3]. Song L, et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014 Aug 15;98(3):267-76.